Indian pharma deals landscape shaped by Covid-19 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Indian pharma deals landscape shaped by Covid-19

By GlobalData Healthcare 07 Oct 2021 (Last Updated October 7th, 2021 09:18)

The number of deals made in the Indian pharma market increased by 22% from 2019 to 2020, likely due to the Covid-19 pandemic.

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only slightly between 2011 and 2019, a considerable increase was confirmed for deals struck in 2020, as illustrated in Figure 1. Between 2019 and 2020, the deal number increased by 22%.

This 2020 increase in deal-making activity, likely triggered by the Covid-19 pandemic, reveals interesting information on India’s capabilities in the pharmaceutical industry. Contract service agreements (CSAs), saw a strong increase in number—from 130 agreements in 2018 to 183 in 2019—and retained their elevated level through the next year. Spiking Covid-19 cases in 2020 drove large pharmaceutical companies to strike deals to outsource clinical research and manufacturing of anti-viral therapeutics and vaccines. Being the world’s largest vaccine producer, India was an optimal market to pursue these agreements. However, CSAs were not the only type of deal that saw an upward trend as a result of the pandemic; strategic alliances, including licensing agreements and partnerships, increased by 40% from 2019 to 2020. The majority of these deals (30%) focused on Covid-19 specifically.

Other deal types were less popular. Mergers and acquisitions (M&As), even though common in the pharma industry, have remained fairly low in number in India, averaging only 54 deals per year from 2011 and 2015 and dropping further between 2016 and 2020 to about 30 deals per year. Similarly, capital raising deals have remained low and static over the past five years.

Over the last decade, an increase in pharma deals has been observed in India driven by continued growth in exports, internal market expansion, as well as the more recent demand for novel vaccines during the Covid-19 pandemic. India’s leading role as the world’s top vaccine manufacturer has attracted many CSAs and strategic alliances in 2020. However, deals such as M&As and capital raisings did not show similar Covid-19 pandemic-associated growth. The deals landscape highlights the current state of India’s pharma market and will likely change substantially if the country shifts its focus more to innovation from its generic products industry.

Up Next